Cell-free DNA methylome and fragmentome analysis for relapse monitoring of Ewing sarcoma. [PDF]
EMBO Molecular MedicineLiquid biopsies and cell-free DNA (cfDNA) offer minimally invasive methods for the diagnosis and monitoring of Ewing Sarcoma (EwS). EwS have a low tumour mutational burden and their detection with plasma cfDNA is challenging.
Florent Mouliere +2 more
exaly +4 more sources
Real-time analysis of the cancer genome and fragmentome from plasma and urine cell-free DNA using nanopore sequencing [PDF]
EMBO Molecular Medicine, 2023 Cell‐free DNA (cfDNA) can be isolated and sequenced from blood and/or urine of cancer patients. Conventional short‐read sequencing lacks deployability and speed and can be biased for short cfDNA fragments.
Florent Mouliere +2 more
exaly +4 more sources
Longitudinal cell-free DNA methylome and fragmentome profiles in health uncover signatures of cell type and demographic origin. [PDF]
Genome MedicineBackground Cell-free DNA (cfDNA) is a powerful analyte for liquid biopsy applications. However, the composition and fragmentation of cfDNA in health remains incompletely characterized. Understanding this baseline variation is key to advancing cfDNA-based
Joris R Vermeesch +2 more
exaly +4 more sources
Early detection and subtyping of gastric cancer: A cell-free DNA fragmentome-based liquid biopsy method. [PDF]
IScienceSummary: Cell-free DNA (cfDNA) in plasma provides attractive opportunities for early cancer diagnosis. This study aimed to establish gastric cancer (GC) artificial intelligence algorithms (GC-AIAs) based on cfDNA fragmentome for GC’s early detection and ...
Ziao Lin, Wenjia Liu
exaly +4 more sources
qMAP decodes RNA fragmentation dynamics in development and disease [PDF]
Molecular Systems BiologyNoncanonical small RNAs, such as tRNA-derived (tsRNAs) and rRNA-derived (rsRNAs) fragments, are more abundant than microRNAs and arise from selective cleavage events rather than random degradation.
Hukam C Rawal +5 more
doaj +3 more sources
Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection [PDF]
Cancer DiscoveryLung cancer screening via annual low-dose computed tomography (LDCT) has poor adoption. We conducted a prospective case-control study among 958 individuals eligible for lung cancer screening to develop a blood-based lung cancer detection test that when ...
Peter Bach +2 more
exaly +7 more sources
A method of comprehensive sequencing analysis of the small RNA fragmentome (RiboMarker). [PDF]
RnaCirculating cell-free nucleic acids (cfDNA and cfRNA) found in blood and other biofluids are promising biomarkers for cancer. However, current methods exploiting tumor-derived cfDNA (ctDNA) are not sensitive enough in detecting minimal residual disease and early stages of cancer when it is more treatable.
Sergio Barberan-Soler, Sergei A Kazakov
exaly +4 more sources
Diagnostics of lung cancer by fragmentated blood circulating cell-free DNA based on machine learning methods [PDF]
Frontiers in MedicineIntroductionMinimally invasive diagnostics based on liquid biopsy makes it possible early detection of lung cancer (LC). The blood plasma circulating cell-free DNA (cfDNA) fragments reflect the genome and chromatin status and are considered as integral ...
Ivan O. Meshkov +17 more
doaj +2 more sources
Nature Communications, 2023 Multimodal epigenetic characterization of cell-free DNA (cfDNA) could improve the performance of blood-based early cancer detection. However, integrative profiling of cfDNA methylome and fragmentome has been technologically challenging. Here, we adapt an
Fenglong Bie +24 more
doaj +2 more sources
Liquid biopsy for early detection of hepatocellular carcinoma [PDF]
Frontiers in Medicine, 2023 Hepatocellular carcinoma (HCC) is a highly prevalent and lethal cancer globally. Over 90% of HCC cases arise in the context of liver cirrhosis, and the severity of the underlying liver disease or advanced tumor stage at diagnosis significantly limits ...
Ioana Manea +20 more
doaj +2 more sources